Home » Stocks » IKT

Inhibikase Therapeutics, Inc. (IKT)

Stock Price: $6.70 USD 0.10 (1.52%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
After-hours: $6.80 +0.10 (1.49%) Jan 25, 7:37 PM
Market Cap 66.83M
Revenue (ttm) 802,425
Net Income (ttm) -4.53M
Shares Out 10.05M
EPS (ttm) -0.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $6.70
Previous Close $6.60
Change ($) 0.10
Change (%) 1.52%
Day's Open 6.89
Day's Range 6.57 - 6.86
Day's Volume 90,308
52-Week Range 6.53 - 9.90

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 3 weeks ago

ATLANTA, Jan. 4, 2021 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and rela...

PRNewsWire - 4 weeks ago

ATLANTA, Dec. 28, 2020 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase"), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and r...

PRNewswire - 1 month ago

/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related...

NASDAQ - 2 months ago

Eight SPACs went public this past week but no IPOs, as all three scheduled deals postponed or withdrew. New filing activity picked up, led by long-awaited delivery service unicorn DoorDash (DA...

NASDAQ - 2 months ago

Inhibikase Therapeutics, a clinical stage biotech developing kinase inhibitors for Parkinson's and related disorders, lowered the proposed deal size for its upcoming IPO on Tuesday. The Atlant...

BioSpace - 5 months ago

Inhibikase Files Registration Statement for Proposed Initial Public Offering - read this article along with other careers information, tips and advice on BioSpace

About IKT

Inhibikase Therapeutics, a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of Parkinson's Disease, dysphagia, and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It offers products comprise IkT-01427, a product candidate... [Read more...]

Industry
Biotechnology
IPO Date
Dec 23, 2020
CEO
Milton H. Werner
Employees
2
Stock Exchange
NASDAQ
Ticker Symbol
IKT
Full Company Profile

Financial Performance

In 2019, IKT's revenue was $1.12 million, a decrease of -72.22% compared to the previous year's $4.04 million. Losses were -$5.72 million, 165.9% more than in 2018.

Financial Statements